JP2008543890A5 - - Google Patents

Download PDF

Info

Publication number
JP2008543890A5
JP2008543890A5 JP2008517321A JP2008517321A JP2008543890A5 JP 2008543890 A5 JP2008543890 A5 JP 2008543890A5 JP 2008517321 A JP2008517321 A JP 2008517321A JP 2008517321 A JP2008517321 A JP 2008517321A JP 2008543890 A5 JP2008543890 A5 JP 2008543890A5
Authority
JP
Japan
Prior art keywords
vaccine
pharmaceutical composition
composition
immunogenic
mycobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008517321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543890A (ja
JP5219808B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2006/000356 external-priority patent/WO2006136162A2/en
Publication of JP2008543890A publication Critical patent/JP2008543890A/ja
Publication of JP2008543890A5 publication Critical patent/JP2008543890A5/ja
Application granted granted Critical
Publication of JP5219808B2 publication Critical patent/JP5219808B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008517321A 2005-06-23 2006-06-20 改良された結核ワクチン Expired - Fee Related JP5219808B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500924 2005-06-23
DKPA200500924 2005-06-23
DKPA200501393 2005-10-05
DKPA200501393 2005-10-05
PCT/DK2006/000356 WO2006136162A2 (en) 2005-06-23 2006-06-20 Tuberculosis vaccines comprising antigens expressed during the latent infection phase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013001657A Division JP2013121959A (ja) 2005-06-23 2013-01-09 改良された結核ワクチン

Publications (3)

Publication Number Publication Date
JP2008543890A JP2008543890A (ja) 2008-12-04
JP2008543890A5 true JP2008543890A5 (https=) 2009-12-24
JP5219808B2 JP5219808B2 (ja) 2013-06-26

Family

ID=37134239

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008517321A Expired - Fee Related JP5219808B2 (ja) 2005-06-23 2006-06-20 改良された結核ワクチン
JP2013001657A Pending JP2013121959A (ja) 2005-06-23 2013-01-09 改良された結核ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013001657A Pending JP2013121959A (ja) 2005-06-23 2013-01-09 改良された結核ワクチン

Country Status (12)

Country Link
US (4) US7968105B2 (https=)
EP (4) EP2163255B1 (https=)
JP (2) JP5219808B2 (https=)
KR (2) KR101035053B1 (https=)
CN (1) CN102836425B (https=)
AU (1) AU2006261445B2 (https=)
BR (1) BRPI0612833A2 (https=)
CA (2) CA2612900C (https=)
ES (1) ES2647070T3 (https=)
IL (3) IL188222A (https=)
MX (1) MX2007016165A (https=)
WO (1) WO2006136162A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529931C1 (de) 1995-08-02 1997-04-03 Mannesmann Ag Plattenkokille zur Erzeugung von Strängen aus Stahl
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
BRPI0809926B8 (pt) * 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
AU2008240181B2 (en) * 2007-04-12 2014-01-09 Jason Fisher Tuberculosis vaccine and method of using same
SI2167124T1 (sl) * 2007-06-29 2012-12-31 Statens Serum Institut Uporaba monomikolil glicerola (mmg) kot adjuvansa
US8741313B2 (en) 2008-01-11 2014-06-03 Emory University Polypeptide vaccine and vaccination strategy against mycobacterium
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
AU2009273130B2 (en) * 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods
WO2010114169A1 (en) * 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
MX2011011186A (es) * 2009-04-24 2012-02-13 Una vacuna antituberculosis tb para evitar la reactivacion.
KR20140015127A (ko) * 2009-07-29 2014-02-06 베른드 헬무트 아담 렘 폴리머 입자 및 이의 용도
TWI638829B (zh) * 2012-07-10 2018-10-21 法商傳斯堅公司 分枝桿菌抗原疫苗
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
RU2520737C1 (ru) * 2013-04-25 2014-06-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почётного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА pESAT6-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-DBD, ШТАММ Escherichia coli, ХИМЕРНЫЙ БЕЛОК ESAT6-DBD И ИХ ПРИМЕНЕНИЕ
RU2539026C1 (ru) * 2013-06-11 2015-01-10 Федеральное государственное бюджетное учреждение "Центральный научно-исследовательский институт туберкулеза" Российской академии медицинских наук РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-CFP10-DBD, РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15 [pREP4, pESAT6-CFP10-DBD], СПОСОБ ПОЛУЧЕНИЯ, ИММОБИЛИЗАЦИИ, КОНЦЕНТРИРОВАНИЯ И ОЧИСТКИ РЕКОМБИНАНТНОГО БЕЛКА ESAT6-CFP10-DBD НА ДЕКСТРАНЕ, РЕКОМБИНАНТНЫЙ БЕЛОК ESAT6-CFP10-DBD И ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ БЕЛОК ESAT6-CFP10-DBD
ES2925950T3 (es) 2013-06-25 2022-10-20 Int Aids Vaccine Initiative Inc Composiciones para la tuberculosis y procedimientos de uso de las mismas
WO2015104380A1 (en) * 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
AU2017285424B2 (en) * 2016-06-16 2022-08-18 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
CN107970444B (zh) * 2016-10-25 2022-03-01 中国人民解放军第三0九医院 复合佐剂及含有该复合佐剂的疫苗
EP3983011A1 (en) 2019-06-14 2022-04-20 Statens Serum Institut Fusion proteins for tuberculosis vaccines
EP4217066A4 (en) * 2020-09-23 2024-10-23 The General Hospital Corporation BCG VACCINES TO PREVENT COVID-19 AND OTHER INFECTIOUS DISEASES
KR102709729B1 (ko) * 2020-12-04 2024-09-25 주식회사 제넥신 결핵의 예방 또는 치료용 약학적 조성물
CN115598041B (zh) * 2021-07-07 2025-08-19 中国科学院微生物研究所 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用
CN118765203A (zh) 2022-02-21 2024-10-11 史坦恩斯血清研究所 一种新型阳离子佐剂组合物
CN117531001A (zh) * 2023-11-15 2024-02-09 首都医科大学附属北京胸科医院 结核分枝杆菌毒素抗毒素系统及其相关应用
CN118108815B (zh) * 2024-04-23 2024-07-23 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1331C (da) 1897-11-15 Hans Daae Militær- og Skilygte.
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
DE69535914D1 (de) * 1994-09-20 2009-03-26 Hitachi Chemical Co Ltd Polynukleotide die einen antigenes polypeptid aus chlamydia pneumoniae kodieren
PT832093E (pt) 1995-06-07 2006-12-29 Sanofi Pasteur Inc Expressão de lipoproteínas
US20040018574A1 (en) * 1998-08-25 2004-01-29 Marcel Behr Molecular differences between species of the M. tuberculosis complex
ES2277855T3 (es) 1999-09-30 2007-08-01 Neurogen Corporation Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas.
AU2001250294A1 (en) 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
WO2002004018A2 (en) 2000-07-10 2002-01-17 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
EP1390468A4 (en) * 2001-04-23 2004-09-22 Elitra Pharmaceuticals Inc IDENTIFICATION OF ESSENTIAL GENES OF ASPERGILLUS FUMIGATUS AND METHOD OF USE
JP2005508613A (ja) * 2001-07-04 2005-04-07 ヘルス プロテクション エージェンシー 潜伏中に発現されるマイコバクテリア抗原
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines

Similar Documents

Publication Publication Date Title
JP2008543890A5 (https=)
JP2008539187A5 (https=)
US11224646B2 (en) Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis
Kim et al. Treatment of latent tuberculosis infection and its clinical efficacy
Ingolotti et al. DNA vaccines for targeting bacterial infections
JP2013507907A5 (https=)
JP2012524733A5 (https=)
CN102413837B (zh) 预防再激活的结核病tb疫苗
Huygen On the use of DNA vaccines for the prophylaxis of mycobacterial diseases
JP2008530245A5 (https=)
HRP20120331T1 (hr) Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis
JP2008529558A5 (https=)
EP3134116B1 (en) New m.tuberculosis vaccines
BRPI0905725B1 (pt) vacina e embalagem farmacêutica
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
JP2015536309A (ja) 結核菌(m.tuberculosis)ワクチン
JP2017505605A5 (https=)
Kaufmann Tuberculosis vaccine development at a divide
CN101745104A (zh) 含有复合佐剂的结核亚单位疫苗
WO2005061534A3 (en) Improved tuberculosis vaccines
Mobed DNA Based Vaccines against Tuberculosis; Recent Progress and Discovery Research in Vaccine Development and Delivery System
Avarvand et al. The roles of latency-associated antigens in tuberculosis vaccines
BR112012011395B1 (pt) Uso de uma fonte de l3 e/ou l5 como uma vacina ou como um diagnóstico para uma doença parasítica
Li et al. Improved humoral immunity against tuberculosis ESAT-6 antigen by chimeric DNA prime and protein boost strategy
ES2364698T3 (es) Composición para inmunizar contra mycobacterium.